Education
About Us
Working with TipRanks
Follow Us
Sinovac Biotech (SVA)
NASDAQ:SVA
SVA Stock Chart & Stats
$6.47
--
Market closed
$6.47
--
Day’s Range― - ―
52-Week Range$6.25 - $6.58
Previous CloseN/A
VolumeN/A
Average Volume (3M)8.23K
Market Cap
$460.27M
Enterprise ValueN/A
Total Cash (Recent Filing)$11.22B
Total Debt (Recent Filing)$298.98M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0%
Share Statistics
EPS (TTM)N/A
Shares Outstanding71,860,700
10 Day Avg. Volume8,227
30 Day Avg. Volume8,227
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.07
Price to Sales (P/S)1.44
P/FCF Ratio-15.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sinovac Biotech News
SVA FAQ
What was Sinovac Biotech’s price range in the past 12 months?
Sinovac Biotech lowest stock price was $6.25 and its highest was $6.58 in the past 12 months.
What is Sinovac Biotech’s market cap?
Sinovac Biotech’s market cap is $460.27M.
When is Sinovac Biotech’s upcoming earnings report date?
Sinovac Biotech’s upcoming earnings report date is May 04, 2026 which is in 139 days.
How were Sinovac Biotech’s earnings last quarter?
Currently, no data Available
Is Sinovac Biotech overvalued?
According to Wall Street analysts Sinovac Biotech’s price is currently Overvalued.
Does Sinovac Biotech pay dividends?
Sinovac Biotech pays a Notavailable dividend of $55 which represents an annual dividend yield of 0%. See more information on Sinovac Biotech dividends here
What is Sinovac Biotech’s EPS estimate?
Sinovac Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinovac Biotech have?
Sinovac Biotech has 71,860,700 shares outstanding.
What happened to Sinovac Biotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sinovac Biotech?
Currently, no hedge funds are holding shares in SVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sinovac Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.03%
Trailing 12-Months
Company Description
Sinovac Biotech
Sinovac Biotech Ltd. (SVA) is a leading biopharmaceutical company focused on research, development, production, and commercialization of vaccines that protect against infectious diseases. Operating primarily in the healthcare and biotechnology sectors, Sinovac is renowned for its extensive portfolio of vaccines, including those for influenza, hepatitis, and COVID-19. The company is headquartered in Beijing, China, and it plays a crucial role in global public health by providing high-quality vaccines to domestic and international markets.
Technical Analysis
Ocugen
―
Korro Bio
―
Foghorn Therapeutics
―
Opthea Limited Sponsored ADR
―
Vor Biopharma
―
Ownership Overview
―
Insiders
0.04% Mutual Funds
12.69% Other Institutional Investors
87.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---